RecruitingAccepts healthy volunteersPhase 1

Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose

Vertex Pharmaceuticals Incorporated · NCT07868926

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Status re-checked against ClinicalTrials.gov within the last 12 hours.

The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.

Being studied: 14C-VX-407

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive
A total body weight of more than (>) 50 kg
Participants must have regular bowel movements (i.e., average of more than or equal to (>=) 1 and less than or equal to (\<=)3 stools per day)

Key Exclusion Criteria

History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
Exposure to any nonenvironmental radiation (e.g., diagnostic medical imaging or occupational exposure) within 12 months before study drug administration
Participation in more than 1 radiolabeled study (if the previous study's radiation exposure is unknown) or participation in more than 3 radiolabeled studies (if the previous studies' radiation exposure is known) in the 12 months before dosing or if the annual whole-body radiation exposure from all previous studies (including this dosing) is more than the FDA-allowed maximum whole body radiation exposure of 5000 mrem

Other protocol defined Inclusion/Exclusion criteria will apply.